Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection

R. van Gijn, H. Rosing, W. W. ten Bokkel Huinink, O. van Tellingen, J. B. Vermorken, A. J M Liefting, R. Bruno, H. M. Pinedo, J. H. Beijnen

Research output: Contribution to journalArticle

Abstract

Intoplicine, a benzopyrido-indole derivative, is a novel anticancer agent currently under phase I clinical evaluation. A selective, sensitive normal-phase high-performance liquid chromatographic (HPLC) assay with fluorescence detection, suitable for the determination of intoplicine in human plasma and whole blood, is described. The sample pretreatment involves a protein precipitation step with 2-propanol. The reported assay was validated, and the stability of the analyte in plasma, in whole blood and in the extraction fluid was investigated. The method has been implemented in a pharmacokinetic phase I clinical trial with intoplicine given as a 24-h intravenous infusion.

Original languageEnglish (US)
Pages (from-to)299-306
Number of pages8
JournalJournal of Chromatography B: Biomedical Sciences and Applications
Volume614
Issue number2
DOIs
StatePublished - May 5 1993
Externally publishedYes

ASJC Scopus subject areas

  • Chemistry(all)
  • Clinical Biochemistry
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection'. Together they form a unique fingerprint.

  • Cite this